Skip to main content
Family Medicine
ALL Specialities
ALL Specialities
/
Family Medicine
CME
COVID-19 Updates
The Journal of Family Practice
Current Issue
Past Issues
Author Guidelines
Specialties
Addiction Medicine
Cardiology
Dermatology
Diabetes
Endocrinology
Gastroenterology
Geriatrics
Hematology
Hepatology
Hospice & Palliative Medicine
Immunology
Infectious Diseases
Men's Health
Mental Health
Nephrology
Neurology
Oncology
Pain
Pediatrics
Pulmonology
Rheumatology
Sleep Medicine
Transgender Health
Women's Health
For Residents
Residents' Rapid Review
Multimedia
Audio
All Podcasts
Practice Alert Podcast
Video
3-in-3
Watch & Learn
Latest News
SGLT2 inhibitors, GLP-1 RAs are effective, but costly in T2D
Publish date:
July 10, 2019
By
Randy Dotinga
Katie Lennon
Recommended Reading
Aggressive lowering of LDL cholesterol: Is it a good idea?
MDedge Family Medicine
Do black patients with type 2 diabetes gain cardiac benefit from the SGLT2 and GLP-1 drugs?
MDedge Family Medicine
FDA issues warning on insulin pump cybersecurity weakness
MDedge Family Medicine
Surprise! High-fat dairy may protect against metabolic syndrome
MDedge Family Medicine
To help patients stay on diabetes regimens: Communicate, educate, and use technology
MDedge Family Medicine
CAROLINA findings reaffirm linagliptin’s safety, free glimepiride of CV-risk stigma
MDedge Family Medicine
New findings cast more doubt on ‘fat-but-fit’ theory
MDedge Family Medicine
VOC-sniffing necklace may support early detection of hypoglycemia
MDedge Family Medicine
Mortality caused by chronic liver disease in setting of diabetes continues to rise
MDedge Family Medicine
Metformin linked to lower dementia risk in black patients
MDedge Family Medicine
Diabetes
All Specialties